US Nuclear Medicine Community to Benefit from a New Supplier of Technetium-99m Generators Produced Using Low Enriched Uranium Sourced Molybdenum-99

Share Article

US Radiopharmaceuticals (USR) and the Australian Nuclear Science and Technology Organization (ANSTO) are pleased to announce they have entered into an agreement, which will enable USR to establish a Technetium-99m generator production facility in Denton, TX.

US Radiopharmaceuticals (USR) and the Australian Nuclear Science and Technology Organization (ANSTO) are pleased to announce they have entered into an agreement, which will enable USR to establish a Technetium-99m generator production facility in Denton, TX.

The agreement, which allows USR to manufacture the Australian designed Technetium-99m (Tc-99m) generators utilizing molybdenum-99, sourced from 100% Low Enriched Uranium (LEU) for distribution in the Americas. Under the terms of the agreement, USR will become the only US generator manufacturer using LEU Mo-99 for 100% of their generators. USR has secured long-term supply contracts guaranteeing year round availability of LEU Mo-99 from both the ANSTO OPAL reactor in Australia and the NTP SAFARI-1 reactor in South Africa.

“USR understands the increasing importance of having a US manufacturer dedicated to sourcing medical isotopes without the use of Highly Enriched Uranium and see this initiative as a major leap forward for the nuclear medicine community in the US", said CEO, Paul Crowe. “We are proud to be the first US Company that will supply 100% LEU Tc-99m generators and are a strong supporter of the United States National Nuclear Security Administration efforts to reduce the use of HEU in medical isotope production”. “We anticipate our announcement today will go some way to alleviate the US Governments concerns associated with non-proliferation and also address recent technetium generator shortages in the US nuclear medicine community”.

The ANSTO generator having been used routinely in Australia and other countries for over 30 years are fully compatible with current usage practices in the United States. “It is a major milestone for ANSTO to be able to deliver our domestic technology into the US market. ANSTO has always been a LEU Mo-99 producer and our current production facility was established in 2008. We have many years of demonstrated robust and reliable manufacturing so ANSTO was an obvious partner for USR’s business plans”, said ANSTO CEO, Dr. Adi Paterson.

USR customers will be able to take full advantage of the recent announcement by the Centers for Medicare and Medicaid Services (CMS) to provide higher reimbursement for technetium produced from LEU-based sources, maintain efficiency in the pharmacy and be assured of stable pricing due to the USR generators being unaffected by proposed federal tariffs on HEU-based, non-full cost recovery Molybdenum-99.

The USR Tc-99 generator plant is scheduled to begin production Q4 2013.

About Molybdenum-99 and Technetium-99m

Mo-99 is the parent isotope of technetium-99m (Tc-99m), which is used in tens of millions of nuclear medicine diagnostic imaging tests, making it the most widely used medical radioisotope currently. Tc-99m is a critical component of many medical tests including heart, brain, and kidney scans and is also used for diagnosis in some types of tumors. Tc-99m is used from a generator distributed to hospitals and radiopharmacies, where it is combined with a range of chemical compounds to perform diagnostic imaging tests.

About US Radiopharmaceuticals

USR, located in Denton, Texas, is an emerging manufacturer and distributor of licensed radioisotopes and radiopharmaceuticals to both the domestic and international nuclear medicine and molecular imaging communities. The company’s cGMP 85,000 Sq. ft. facility and high-energy accelerators offer manufacturing of traditional SPECT/PET radiopharmaceuticals and R&D capabilities. The USR facility will be reopening in the first quarter of 2013 establishing the company as a reliable supplier of high quality products for the nuclear medicine market.

About ANSTO

ANSTO is Australia's national nuclear research organization and the centre of Australian nuclear expertise. ANSTO operates nuclear science and technology based facilities, including Australia’s nuclear research reactor, OPAL.

On average, each week ANSTO delivers 10,000 patient doses of potentially lifesaving nuclear medicines to over 250 partner hospitals and medical practices across Australia, New Zealand, and South East Asia.

US Radiopharmaceuticals: For inquiries, call 888-902-7779, fax 435-647-5602 or visit our website http://www.usradiopharm.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Paul Crowe
Visit website